Article
Oncology
Hao Li, Chao Liang, Donglin Kuang, Guohao Huang, Mengfan Zhang, Pengfei Chen, Qingzhu Zheng, Wenze Xu, Jianzhuang Ren, Xinwei Han, Xuhua Duan
Summary: This study evaluated the impact of drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) on hepatic fibrosis in hepatocellular carcinoma (HCC) patients. The results showed that DEB-TACE attenuates the progression of hepatic fibrosis and has comparable tolerance to cTACE in treating intermediate- or advanced-stage HCC.
CANCER BIOLOGY & THERAPY
(2023)
Article
Pharmacology & Pharmacy
Guangsheng Zhao, Song Liu, Songbai Chen, Zhizhong Ren, Chuang Li, Jie Bian, Jianlin Wu, Jun Zhou, Yuewei Zhang
Summary: In short-term efficacy, CalliSpheres group showed significantly higher objective response rate and disease control rate compared to the HepaSpheres group; however, there were no significant differences between the two groups in terms of long-term efficacy and safety.
Article
Medicine, General & Internal
Somin Lee, Yong Yeon Jeong, Byung Chan Lee, Sang Soo Shin, Suk Hee Heo, Hyoung Ook Kim, Chan Park, Won Gi Jeong
Summary: This study compared the long-term therapeutic outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) with radiofrequency ablation (RFA) for the initial treatment of a single small hepatocellular carcinoma (HCC). The results showed that RFA had superior local tumor progression and progression-free survival rates compared to DEB-TACE, but there was no significant difference in overall survival rates. Therefore, DEB-TACE may be considered as an efficient substitute for RFA in some patients with a single small HCC who are ineligible for RFA.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Article
Oncology
Jianping Zhao, Jingjing Wang, Yuanxiang Lu, Yang Wu, Dong Kuang, Ying Wang, Hongchang Luo, Anhui Xu, Wanguang Zhang
Summary: The study suggests that neoadjuvant drug-eluting bead transarterial chemoembolization (DTACE) and tislelizumab therapy are safe and beneficial for patients with resectable or borderline resectable hepatocellular carcinoma (HCC), improving pathological results and prognosis.
Article
Oncology
Donglin Kuang, Nan Zhang, Mengfan Zhang, Hao Li, Xinwei Han, Jianzhuang Ren, Xuhua Duan
Summary: The purpose of this study was to investigate the morphological characteristics and clinical significance of peritumor margin enhancement on magnetic resonance (MR) images in hepatocellular carcinoma (HCC) patients after drug-eluting bead transcatheter arterial chemoembolization (DEB-TACE). The results showed that HCC patients with a sharp-type margin enhancement on MR images had lower levels of alpha-fetoprotein (AFP) and longer progression-free survival, indicating a benign prognosis. On the other hand, patients with a rough-type margin enhancement mostly demonstrated malignant growth.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Wenzhe Fan, Bowen Zhu, Xinlin Zheng, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li
Summary: This study investigated the effectiveness and safety of combining sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). The results showed that the combination therapy significantly improved tumor response rates, overall survival, and time to progression compared to sorafenib monotherapy. However, the DTS group had a higher incidence of adverse events during treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Guangshao Cao, Yuyan Liu, Lupeng Li, Xiaoyang Zhao, Ruiqing Liu, Jian Liu, Jianwen Liu, Huicun Cao
Summary: This study compared the occurrence of adverse events (AEs) among radiofrequency ablation (RFA), conventional transarterial chemoembolization (cTACE), and drug-eluting bead TACE (DEB-TACE) in treating HCC patients. It found that cTACE resulted in the highest incidence of AEs, with male gender, bronchial asthma, and disease duration being independent predictive factors for total AEs risk.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Biology
Jung Woo Yi, Hyun Pyo Hong, Myung Sub Kim, Byung Seok Shin, Heon-Ju Kwon, Byung Ik Kim, Won Sohn
Summary: This study compared the efficacy and safety of 70-150 μm and 100-300 μm doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) as first-line treatment for hepatocellular carcinoma (HCC). The results showed no significant difference in tumor response and adverse events between the two groups, indicating both were effective and safe treatment options.
Review
Oncology
Khalid I. Bzeizi, Mohammad Arabi, Negar Jamshidi, Ali Albenmousa, Faisal M. Sanai, Waleed Al-Hamoudi, Saad Alghamdi, Dieter Broering, Saleh A. Alqahtani
Summary: DEB-TACE treatment shows better objective response, disease control, and lower all-cause mortality with fewer severe complications compared to C-TACE, while not demonstrating clear superiority in complete or partial response, disease stability, or controlling disease progression.
Article
Biotechnology & Applied Microbiology
Hao Li, Manzhou Wang, Pengfei Chen, Fangzheng Li, Donglin Kuang, Xinwei Han, Jianzhuang Ren, Xuhua Duan
Summary: This study aimed to assess the prevalence of vascular lake (VL) in HCC patients treated with DEB-TACE, and found that VL is associated with better treatment response and survival. There were no significant differences in liver function and adverse events between VL patients and non-VL patients.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Kai-Cai Liu, Wei-Fu Lv, Dong Lu, Chang-Long Hou, Jun Xie, Yu-He Lu, Qi-Sheng Cao, Yu-Lin Tan, Ying-Zhan Zhang, Jie Liu
Summary: DEB-TACE treatment shows potential efficacy and safety in patients with HCC refractory to TACE, making it a promising option after the failure of conventional treatment. Further studies are needed to confirm its efficacy.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Yonghua Bi, Kewei Ren, Jianzhuang Ren, Ji Ma, Xinwei Han
Summary: DEB-TACE loaded with oxaliplatin has shown promising outcomes in treating unresectable or recurrent HCC patients, with high response rates and good safety profiles.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, Lynn Huyck, Peter Vanlangenhove, Anja Geerts, Xavier Verhelst, Maridi Aerts, Aude Vanlander, Frederik Berrevoet, Roberto Ivan Troisi, Hans Van Vlierberghe, Luc Defreyne
Summary: This study compared the efficacy and safety of Y-90 glass TARE and DEB-TACE for unresectable HCC. The results showed that TARE conferred superior tumor control and overall survival compared to DEB-TACE. Both treatments had similar safety profiles.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lei Zhang, Jun-Hui Sun, Jian-Song Ji, Bin-Yan Zhong, Guan-Hui Zhou, Jing-Jing Song, Zhong-Heng Hou, Peng Huang, Shen Zhang, Zhi Li, Xiao-Li Zhu, Cai-Fang Ni
Summary: In the treatment of unresectable HCC patients, DEB-TACE was associated with higher rates of hepatobiliary injury and severe abdominal pain compared to cTACE, while local tumor disease control rates did not differ significantly between the two approaches.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2021)
Article
Multidisciplinary Sciences
William T. N. Culp, Eric G. Johnson, Michelle A. Giuffrida, Robert B. Rebhun, James K. Cawthra, Heidi A. Schwanz, Jenna H. Burton, Michael S. Kent
Summary: This study describes the use of a novel drug-eluting microsphere in transarterial chemoembolization for dogs with non-resectable hepatic neoplasia. The results show significant reduction in tumor volume and improvement in clinical signs.
